AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RACE ONCOLOGY LTD

1.900

+0.0402.15%

Volume:18

Turnover:34

Market Cap:372.53M

PE:-30.69

High:1.900

Open:1.900

Low:1.900

Close:1.860

52wk High:4.900

52wk Low:1.840

Shares:196.07M

Float Shares:121.21M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.062

EPS(LYR):-0.062

ROE:-42.28%

ROA:-23.40%

PB:10.22

PE(LYR):-30.69

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.97%

Capital Flow

Inflow:

Outflow:

News

Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors

MT Newswires Live

Racura Oncology Says Safety Review Committee Completes Review of HARNESS-1 Trial Single-Patient First Group Safety Data

MT Newswires Live

Racura Oncology Secures Ethics Committee Approval for Lung Cancer Clinical Trial for Trial Sites Outside Victoria

MT Newswires Live

Racura Oncology Doses First Patient in Phase 1 Trial of Lung Cancer Drug Candidate

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/RAC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":1.9,"timestamp":1790900656283,"preClose":1.86,"halted":0,"volume":18,"delay":0,"changeRate":0.02150537634408592,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":196068940,"eps":-0.0619,"marketStatus":"Trading","change":0.04,"latestTime":"10-02 10:26:31 AEST","open":1.9,"high":1.9,"low":1.9,"amount":34,"amplitude":0,"askPrice":1.925,"askSize":346,"bidPrice":1.905,"bidSize":342,"shortable":3,"etf":0,"ttmEps":-0.0619,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790920800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":1.86,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":0.002733,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAC.AU","preClose":1.86,"auctionPrice":1.9,"auctionVolume":18,"auctionTime":1790898407765,"referenceTime":1790850603090,"auction":1,"marketStatus":"盘前竞价","timestamp":1790898407765}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-23.40%","roe":"-42.28%","lyrEps":-0.0619,"volumeRatio":0.002733,"shares":196068940,"dividePrice":0,"high":1.9,"amplitude":0,"preClose":1.86,"low":1.9,"week52Low":1.84,"pbRate":"10.22","psRate":"132.53","week52High":4.9,"institutionHeld":0,"latestPrice":1.9,"committee":-0.005814,"eps":-0.0619,"divideRate":0,"volume":18,"delay":0,"ttmEps":-0.0619,"open":1.9,"prevYearClose":2.73,"prevWeekClose":2.05,"prevMonthClose":1.89,"prevQuarterClose":1.89,"fiveDayClose":2.05,"twentyDayClose":2.1,"sixtyDayClose":2.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664888926","title":"Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888926","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888926?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:24","pubTimestamp":1788222288,"startTime":"0","endTime":"0","summary":"Racura Oncology  said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4157","RAC.AU","LU0757428866.USD","AEIS","LU1815336091.USD","LU2089985449.USD","LU0274383776.USD","IE0031619046.USD","IE00B19Z4B17.USD","BK7508","LU2931357623.SGD","BK7067","IE00B66KJ199.SGD","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655834301","title":"Racura Oncology Says Safety Review Committee Completes Review of HARNESS-1 Trial Single-Patient First Group Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2655834301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655834301?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:46","pubTimestamp":1785286003,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the Safety Review Committee completed its review of safety data from the HARNESS-1 trial single-patient first group who received a dose of its RC220 drug candidate at 50 milligrams per square meter with osimertinib 80 milligrams daily, according to a Wednesday Australian bourse filing.No dose-limiting toxicities or treatment-related safety concerns were identified during the safety observation period. However, the patient reported moderate symptoms consistent with colitis, an inflammation of the large intestine or colon, after the period ended. The cause of these symptoms has not yet been determined, and clinical investigations are ongoing.The observed colitis was not considered a dose-limiting toxicity or treatment-related adverse event. However, the committee recommended that one additional patient receive the drug candidate at 50 milligrams per square meter with 80 milligrams of osimertinib before dose escalation to 100 mg/m2 occurs, as a prudent precaution.The","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648310506","title":"Racura Oncology Secures Ethics Committee Approval for Lung Cancer Clinical Trial for Trial Sites Outside Victoria","url":"https://stock-news.laohu8.com/highlight/detail?id=2648310506","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648310506?lang=en_us&edition=fundamental","pubTime":"2026-07-03 08:30","pubTimestamp":1783038637,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the Bellberry human research ethics committee approved the HARNESS-1 lung cancer clinical trial, for Australian private hospital sites and eligible public hospital sites outside Victoria, allowing for additional clinical trial sites to be activated, according to a Friday Australian bourse filing.The study is evaluating the safety, tolerability, and pharmacokinetics of RC220, the firm's proprietary formulation of bisantrene, in combination with osimertinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations. Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations.The human research ethics committee for the St Vincents Hospital in Melbourne had earlier approved the lead clinical trial site, Monash Health. The hospital committee also approved the inclusion of Austin Health in Victoria.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4095","VCCTF","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646844292","title":"Racura Oncology Doses First Patient in Phase 1 Trial of Lung Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2646844292","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646844292?lang=en_us&edition=fundamental","pubTime":"2026-06-25 07:18","pubTimestamp":1782343113,"startTime":"0","endTime":"0","summary":"Racura Oncology  dosed the first patient in a phase 1 clinical trial evaluating its RC220 drug candidate in combination with osimertinib for the treatment of non-small cell lung cancer, according to a Thursday filing with the Australian bourse.The company said no adverse events were seen during or after the first RC220 infusion.The study is using single-patient cohorts for the first three dose escalation stages before advancing to larger cohorts to determine the maximum tolerated dose. Additional clinical trial sites are expected to open in the coming months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAC.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.009686}]}}